CHRS Stock Price Prediction 2026-2027
AI-powered forecast for Coherus Oncology Inc
Based on Wall Street consensus estimate - Medium Confidence
Current Price
$1.99
Price Targets for 2027
Bear Case
$5.74
+188.3%
Base Case
$6.75
+239.2%
Bull Case
$7.76
+290.1%
Prediction Tracking
Coming Soon for CHRS
Tracking begins January 2026
We are building a comprehensive track record of our AI predictions. Check back to see how our forecasts perform against actual results.
Upcoming Events for CHRS
Key Factors Influencing CHRS Stock
Bullish Factors
- Revenue growth of 0.6% year-over-year
- Significant upside potential to bull case target
- Market position and competitive advantages
Risk Factors
- Market volatility and macroeconomic factors
- Competitive pressures in Biotechnology
Prediction Methodology
These predictions are based on the Wall Street consensus price target of $6.75.
Bull and bear cases are calculated with a reasonable spread around the consensus based on historical volatility.
Get Real-Time Analysis
Access live data, AI insights, and detailed valuations for CHRS
Frequently Asked Questions
What is CHRS stock price today?
CHRS (Coherus Oncology Inc) stock is trading at $1.99 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).
Is CHRS stock going up or down today?
CHRS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.
Should I buy CHRS stock now?
The decision to buy CHRS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.
Is CHRS a buy, hold, or sell right now?
Our AI-powered analysis provides buy/hold/sell recommendations for CHRS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.
Is CHRS stock overvalued or undervalued?
Use our DCF valuation calculator to determine if CHRS is overvalued or undervalued based on fundamental analysis and future cash flow projections.
What is CHRS's P/E ratio?
P/E ratio data for CHRS will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.
What is CHRS's market cap?
CHRS (Coherus Oncology Inc) has a market capitalization of $0.30 billion, making it a small-cap stock.
What is CHRS's price to book ratio?
CHRS trades at a price-to-book (P/B) ratio of 4.86, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.
Does CHRS pay dividends?
CHRS does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.
What is CHRS's dividend yield?
CHRS does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.
Is CHRS stock a good long-term investment?
CHRS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.
What is CHRS's revenue growth rate?
CHRS has shown revenue growth of 0.6% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.
Is CHRS profitable?
Yes, CHRS is profitable with a profit margin of 4.0%. This indicates the company generates 4.0 cents of profit for every dollar of revenue.
What are the risks of investing in CHRS?
Key risks for CHRS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.
How does CHRS compare to its competitors?
Compare CHRS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize CHRS's performance and positioning.
What is CHRS's stock price target for 2026?
Our AI model provides price targets for CHRS based on fundamental analysis: Bull case $2.59 (+30%), Base case $2.29 (+15%), Bear case $1.79 (-10%). Visit our prediction page for detailed forecasts.
What do analysts say about CHRS?
Wall Street analysts provide ratings (buy/hold/sell) and price targets for CHRS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.
When is CHRS's next earnings report?
CHRS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.